Q4 2021 13F Holders as of 12/31/2021
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
40.6M
-
Number of holders
-
92
-
Total 13F shares, excl. options
-
15.7M
-
Shares change
-
+1.05M
-
Total reported value, excl. options
-
$918M
-
Value change
-
+$68.3M
-
Number of buys
-
47
-
Number of sells
-
-37
-
Price
-
$58.51
Significant Holders of Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) as of Q4 2021
110 filings reported holding KROS - Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q4 2021.
Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) has 92 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 15.7M shares
of 40.6M outstanding shares and own 38.66% of the company stock.
Largest 10 shareholders include FMR LLC (3.5M shares), ORBIMED ADVISORS LLC (1.68M shares), Deep Track Capital, LP (1.3M shares), BlackRock Inc. (1.29M shares), ALKEON CAPITAL MANAGEMENT LLC (926K shares), Nantahala Capital Management, LLC (797K shares), VANGUARD GROUP INC (734K shares), STATE STREET CORP (655K shares), First Light Asset Management, LLC (552K shares), and Octagon Capital Advisors LP (340K shares).
This table shows the top 92 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.